180464-92-0

Basic information

• Product Name: Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI)
• Synonyms: Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI);methyl 3-formylbicyclo[1.1.1]pentane-1-carboxylate;Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester
• CAS NO: 180464-92-0
• Molecular Formula: C₈H₁₀O₃
• Molecular Weight: 154.1632
• Product Categories: ALDEHYDE;CARBOXYLICESTER
• Mol File: 180464-92-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI)(180464-92-0)
• EPA Substance Registry System: Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI)(180464-92-0)

Safety Data

• Hazardous Substances Data: 180464-92-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI) is used as a key intermediate in organic synthesis for the creation of complex organic molecules. Its unique structure and reactivity make it a valuable component in the synthesis of various compounds.
Used in Pharmaceutical Production:
In the pharmaceutical industry, Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI) is employed as an intermediate in the production of various drugs. Its role in the synthesis of active pharmaceutical ingredients contributes to the development of new medications with potential therapeutic benefits.
Used in Agrochemical Production:
Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI) also finds application in the agrochemical industry, where it serves as an intermediate in the synthesis of various agrochemicals. Its use in this field highlights its versatility and importance in the development of agricultural products.
Used in Medicinal Chemistry Research:
Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI) is utilized in medicinal chemistry for the development of new drug candidates. Its unique properties and reactivity make it a promising building block for the design and synthesis of innovative pharmaceuticals with potential therapeutic applications.
It is crucial to handle and use Bicyclo[1.1.1]pentane-1-carboxylic acid, 3-formyl-, methyl ester (9CI) with caution due to its potential hazards and toxicological properties. Proper safety measures should be implemented to ensure the safe use of this chemical compound in various applications.

Upstream product

• 115913-32-1 dimethyl bicyclo<1.1.1>pentane-1,3-dicarboxylate 
• 115913-31-0 1,3-bis(chlorocarbonyl)bicyclo<1.1.1>pentane 
• 83249-10-9 3‐(methoxycarbonyl)bicyclo[1.1.1]pentane‐1‐carboxylic acid 
• 115913-30-9 1,1′-(bicyclo[1.1.1]pentane-1,3-diyl)bis(ethan-1-one) 
• 56842-95-6 bicyclo<1.1.1>pentane-1,3-dicarboxylic acid 
• 311-75-1 bicyclo[1.1.1]pentane 
• 180464-87-3 methyl 3-(hydroxylmethyl)bicyclo[1.1.1]pentane-1-carboxylate 

Downstream Products

• 180464-96-4 3-[(S)-Cyano-((R)-2-hydroxy-1-phenyl-ethylamino)-methyl]-bicyclo[1.1.1]pentane-1-carboxylic acid methyl ester 
• 180465-00-3 3-[(R)-Cyano-((R)-2-hydroxy-1-phenyl-ethylamino)-methyl]-bicyclo[1.1.1]pentane-1-carboxylic acid methyl ester 

Relevant articles and documents

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

The invention provides anti-VISTA antibody drug conjugates which may be used for targeted delivery of anti-inflammatory agents such as steroids to immune cells, e.g., myeloid cells. The invention also provides methods of using anti-VISTA antibody drug conjugates in the treatment of inflammatory and/or autoimmune conditions and/or for alleviating the toxicity of anti-inflammatory agents such as steroids.

INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

CARDIAC SARCOMERE INHIBITORS

Provided are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2A, R2B, R3, R4, and R5 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE

The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

COMPOUNDS AND METHOD OF USE

This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.

TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

Bicyclo[1.1.1]pentane-Derived Building Blocks for Click Chemistry

Syntheses of bicyclo[1.1.1]pentane-derived azides and terminal alkynes – interesting substrates for click reactions – are described. With a few exceptions, these compounds were prepared in two or three steps starting from common synthetic intermediates – the corresponding carboxylic acids. The key step in the synthesis of 1-azidobicyclo[1.1.1]pentanes is a copper-catalysed diazo-transfer reaction with imidazole-1-sulfonyl azide. The preparation of bicyclo[1.1.1]pentyl-substituted alkynes relies on a Seyferth–Gilbert homologation with dimethyl 1-diazo-2-oxopropylphosphonate (Ohira–Bestmann reagent). Both types of target compounds were found to be suitable substrates for click reactions, and thus they are promising building blocks for medicinal, combinatorial and bioconjugate chemistry. A practically important side result of this study was a multigram preparation of Boc-monoprotected 1,3-diaminobicyclo[1.1.1]pentane – a representative bicyclic conformationally restricted diamine derivative.

Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs

A convenient synthesis of imatinib, a potent inhibitor of ABL1 kinase and widely prescribed drug for the treatment of a variety of leukemias, was devised and applied to the construction of a series of novel imatinib analogues featuring a number of non-aromatic structural motifs in place of the parent molecule's phenyl moiety. These analogues were subsequently evaluated for their biopharmaceutical properties (e.g., ABL1 kinase inhibitory activity, cytotoxicity). The bicyclo[1.1.1]pentane- and cubane-containing analogues were found to possess higher themodynamic solubility, whereas cubane- and cyclohexyl-containing analogues exhibited the highest inhibitory activity against ABL1 kinase and the most potent cytotoxicity values against cancer cell lines K562 and SUP-B15. Molecular modeling was employed to rationalize the weak activity of the compounds against ABL1 kinase, and it is likely that the observed cytotoxicity of these agents arises through off-target effects.